CCR6抗体

+ +

•  

   

     Gel: 8%SDS-PAGE, Lysate: 40 μg, Lane 1-4: Human bladder transitional cell carcinoma grade 2-3 tissue, HepG2 cell, HT-29 cell, 231 cell lysates, Primary antibody: P04745(CCR6 Antibody) at dilution 1/300, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 30 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human cervical cancer tissue using P04745(CCR6 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

CCR6 (C-C chemokine receptor type 6) is a G protein-coupled receptor (GPCR) predominantly expressed on immune cells, including dendritic cells, T cells (particularly Th17 cells), and B cells. It plays a critical role in immune cell trafficking by binding to its sole ligand, CCL20 (also known as MIP-3α), which is produced at sites of inflammation. This receptor-ligand interaction is crucial for mucosal immunity, inflammatory responses, and the pathogenesis of autoimmune diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease (IBD).

CCR6 antibodies are tools or therapeutic agents designed to target this receptor. In research, they are used to study CCR6-mediated signaling, immune cell migration, and disease mechanisms. Therapeutically, monoclonal antibodies (mAbs) against CCR6 aim to block CCL20 binding or receptor activation, thereby inhibiting the recruitment of pathogenic Th17 cells to inflamed tissues. Several anti-CCR6 mAbs are under preclinical or clinical investigation for autoimmune and inflammatory disorders. For example, some candidates have shown promise in reducing disease severity in models of multiple sclerosis or colitis.

Challenges in developing CCR6 antibodies include ensuring specificity to avoid off-target effects and balancing therapeutic efficacy with potential immunosuppressive risks, given CCR6’s role in normal immune surveillance. Advances in antibody engineering, such as humanized or bispecific designs, aim to enhance targeting precision. Overall, CCR6 antibodies represent a strategic approach to modulating dysregulated immune responses while offering insights into CCR6 biology and its therapeutic potential.